Finally, we assessed the therapeutic potential of “double-punch system” of stem cell-based gene directed enzyme prodrug (CD or CE) and/or IFN-β system for treating prostate cancer in in vitro cellular models. The gene discussed is IFNB1; the disease is prostate carcinoma.